The expanded collaboration will leverage Orbit Discovery’s proprietary screening platform to identify and optimize peptide candidates, combined with Evergreen Theragnostics’ expertise in radiopharmaceutical development and clinical translation.
Radiopharmaceutical Delivery | 04/12/2024 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy